Company-wide revenue
Reported revenue in 2021 ¥577.25B Reported revenue in 2025 ¥610.5B
- growth amount
- +¥33.25B
- growth annualized
- +1.4%
- growth total
- +5.8%
Japanese company profile · 3151
In its FY2025 public filing, VITAL KSK HOLDINGS,INC. reports Pharmaceutical Wholesale Business, Pharmacy business, Wholesale of veterinary medicines, Pharmaceuticals, and 1 other reported businesses. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 株式会社バイタルケーエスケー・ホールディングス
English company name recorded in Japan's EDINET filer data. English company name source
What does this company do?
The business with the highest reported segment profit in FY2025 was Pharmaceutical Wholesale Business.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| Pharmaceutical Wholesale Business | ¥583.85B ↗ | 95.6% | ¥4.92B ↗ |
| Pharmacy business | ¥19.97B ↗ | 3.3% | ¥252M ↗ |
| Wholesale of veterinary medicines | ¥12.63B ↗ | 2.1% | ¥304M ↗ |
| Nursing rental and other services | ¥7.87B ↗ | 1.3% | −¥102M ↗ |
| Pharmaceuticals | — | — | −¥1.31B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
What is growing?
Reported revenue in 2021 ¥577.25B Reported revenue in 2025 ¥610.5B
Reported revenue in 2021 ¥10.4B Reported revenue in 2025 ¥12.63B
Reported revenue in 2022 ¥18.37B Reported revenue in 2025 ¥19.97B
Reported revenue in 2021 ¥553.06B Reported revenue in 2024 ¥575.4B
Reported profit margin in 2022 +0.6%
Reported profit margin in 2025 +1.3%
Reported profit margin in 2021 +0.4%
Reported profit margin in 2024 +0.9%
First reported in 2025
Latest reported revenue ¥583.85B
First reported in 2025
Latest reported revenue ¥7.87B
First reported in 2025
This describes a reported period; it is not a forecast.
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YDSN
View original filing ↗Ask about this company
The source document may be in Japanese.